IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties - Sorbonne Université Access content directly
Journal Articles Trends in Pharmacological Sciences Year : 2015

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties

Abstract

Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing–remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.
Fichier principal
Vignette du fichier
Bayry_IVIg_for.pdf (472.2 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01155485 , version 1 (26-05-2015)

Identifiers

Cite

Jagadeesh Bayry, Hans-Peter Hartung, Srini V Kaveri. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends in Pharmacological Sciences, 2015, 36 (7), pp.419-421. ⟨10.1016/j.tips.2015.04.012⟩. ⟨hal-01155485⟩
114 View
503 Download

Altmetric

Share

Gmail Facebook X LinkedIn More